JP2025509818A - Ｓｈｐ２阻害剤の結晶性塩形態 - Google Patents

Ｓｈｐ２阻害剤の結晶性塩形態 Download PDF

Info

Publication number
JP2025509818A
JP2025509818A JP2024555324A JP2024555324A JP2025509818A JP 2025509818 A JP2025509818 A JP 2025509818A JP 2024555324 A JP2024555324 A JP 2024555324A JP 2024555324 A JP2024555324 A JP 2024555324A JP 2025509818 A JP2025509818 A JP 2025509818A
Authority
JP
Japan
Prior art keywords
cancer
compound
ppm
amino
dihydrospiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509818A5 (enExample
Inventor
キートン ブラウン ケイティ
ジェームズ カウドリー コナー
キース グッドウィン アーロン
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2025509818A publication Critical patent/JP2025509818A/ja
Publication of JP2025509818A5 publication Critical patent/JP2025509818A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024555324A 2022-03-23 2023-03-20 Ｓｈｐ２阻害剤の結晶性塩形態 Pending JP2025509818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23
US63/323,005 2022-03-23
PCT/IB2023/052709 WO2023180898A1 (en) 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor

Publications (2)

Publication Number Publication Date
JP2025509818A true JP2025509818A (ja) 2025-04-11
JP2025509818A5 JP2025509818A5 (enExample) 2026-02-12

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555324A Pending JP2025509818A (ja) 2022-03-23 2023-03-20 Ｓｈｐ２阻害剤の結晶性塩形態

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
TW202346282A (zh) 2023-12-01
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
AR128847A1 (es) 2024-06-19
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
KR20240163705A (ko) 2024-11-19
AU2023238523B2 (en) 2025-10-30
AU2023238523A1 (en) 2024-08-22
MX2024011603A (es) 2024-09-30
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
JP6530792B2 (ja) Ｓｙｋ阻害剤
US20240190843A1 (en) Crystalline form of a shp2 inhibitor
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
TW202519524A (zh) 固態形式
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
CN122003424A (zh) 一种稠环化合物及在kras抑制剂方面的应用
KR20180048635A (ko) Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
TW202545956A (zh) 吡啶並嘧啶類衍生物的晶型、製備方法及其應用
CN114230524A (zh) (5-氟-2-苯胺嘧啶-4-基)氨基-n-羟基苯甲酰胺衍生物及其制备方法与应用
EA019183B1 (ru) Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
RU2658009C2 (ru) Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1н-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
WO2017162611A1 (en) Quinoline-3-carboxamide compounds and their use in treating cancer
US20250214966A1 (en) Crystalline Salt Form Of A SHP2 Inhibitor
CN114728875A (zh) 金属盐及其用途
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
HK40112682A (zh) Shp2抑制剂的结晶盐形式
EP4570800A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
HK40101911A (zh) Shp2抑制剂的晶型
CA3263285A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
CN117460725A (zh) Shp2抑制剂的晶型
RU2845218C2 (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
HK40077267A (en) Metal salts and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260203